Targeting Non-Alcoholic Fatty Liver Disease: Lifestyle, Pharmacotherapy, and Beyond

Non-alcoholic fatty liver disease (NAFLD) has rapidly become one of the most significant liver disorders globally, affecting nearly a quarter of the world’s population. It encompasses a spectrum of liver conditions, starting with simple steatosis (fat accumulation in hepatocytes) and progressing in some individuals to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). This Article Collection aims to explore the latest advancements in NAFLD management, from foundational lifestyle interventions to cutting-edge pharmacological and non-pharmacological strategies.